Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK

Krystal Biotech gets a fresh Buy confirmation and a $310 target from HC Wainwright just as UK regulators approve its gene therapy VYJUVEK for dystrophic epidermolysis bullosa, adding a new commercial leg to the rare-disease story.

Krystal Biotech Inc is back in the spotlight after HC Wainwright reaffirmed its Buy rating and maintained a $310 price target on the stock, while the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for the company’s gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB), according to reports from MarketBeat as of 05/18/2026 and a company news release cited by StockTitan/GlobeNewswire as of 05/18/2026.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Krystal Biotech, Inc.
• Sector/industry: Biotechnology / gene therapy
• Headquarters/country: Pittsburgh, United States
• Core markets: Rare dermatological and respiratory diseases
• Key revenue drivers: VYJUVEK gene therapy and pipeline genetic medicines
• Home exchange/listing venue: Nasdaq (ticker: KRYS)
• Trading currency: USD

Krystal Biotech Inc: core business model

Krystal Biotech Inc focuses on developing and commercializing genetic medicines for serious diseases with high unmet medical need, particularly in dermatology. The company’s approach is built around a proprietary redosable gene delivery platform designed to introduce functional copies of genes directly into affected tissues, as outlined in corporate materials referenced by Invezz as of 05/2026.

The company’s lead product, VYJUVEK (beremagene geperpavec), targets dystrophic epidermolysis bullosa, a rare and often devastating inherited skin disorder caused by mutations in the COL7A1 gene. VYJUVEK is engineered to deliver a functional COL7A1 gene to skin cells, aiming to enable production of type VII collagen, which is critical for anchoring the layers of the skin and supporting proper wound healing, according to the product description summarized in a company release cited by Business Insider as of 05/18/2026.

Krystal Biotech positions itself as a fully integrated biotechnology business, covering research, clinical development, manufacturing and commercialization under one roof. That integrated setup is intended to shorten development timelines, maintain control of product quality and enable rapid geographic expansion once regulatory approvals are secured, according to descriptions repeated in multiple company communications cited by Business Insider as of 05/18/2026.

While Krystal Biotech’s roots are in rare dermatologic diseases, the company is broadening its platform into other areas where local or organ-specific gene delivery could be advantageous. Pipeline disclosures point to programs in respiratory conditions and other genetic disorders, highlighting management’s ambition to build a multi-asset genetic medicines franchise rather than a single-product company, according to summaries in third-party coverage by Invezz as of 05/2026.

Main revenue and product drivers for Krystal Biotech Inc

The main commercial driver for Krystal Biotech is VYJUVEK, which has already obtained approval in the United States for the treatment of dystrophic epidermolysis bullosa and is now expanding into additional geographies. The newly announced MHRA approval in the United Kingdom authorizes VYJUVEK for the treatment of wounds in patients with DEB with COL7A1 mutations from birth, making it the first genetic medicine approved in the UK for this indication, according to a company announcement reported by StockTitan/GlobeNewswire as of 05/18/2026.

Management sees international expansion of VYJUVEK as a key lever for revenue growth, given that patients with DEB are spread across North America, Europe and other regions. The UK approval follows earlier regulatory milestones in the United States and other markets, and the company described the MHRA decision as another important commercial and regulatory step that supports its long-term growth trajectory, according to the same news release cited by StockTitan/GlobeNewswire as of 05/18/2026.

Beyond VYJUVEK, Krystal Biotech is investing in a pipeline of genetic medicines that leverage similar vector technology tailored to different tissues. While specific phase timelines and trial readouts vary by asset, the economics of successful gene therapies in rare diseases can be significant because of high per-patient pricing and durable treatment effects, a dynamic widely discussed in biotechnology sector coverage such as that referenced by Investing.com as of 05/18/2026.

Krystal Biotech’s financial profile reflects its transition from a purely clinical-stage enterprise to a commercial-stage company. Market data compiled by MarketBeat as of 05/2026 show trailing earnings per share of $7.48 and a price-to-earnings ratio of about 39.00, with consensus expectations pointing to EPS growth of roughly 31.83% next year, from $7.98 to $10.52 per share. These metrics underline how heavily the stock’s valuation is tied to future revenue scaling and margin expansion from VYJUVEK and subsequent launches.

According to the same set of data from MarketBeat as of 05/2026, Krystal Biotech’s share price performance has been robust, placing the company among higher-growth biotechnology names. However, earnings expectations imply that the market is also sensitive to the pace of uptake for VYJUVEK in existing markets and the timing of potential approvals in new territories like the European Union or additional Asia-Pacific countries.

Latest catalysts: HC Wainwright reiteration and UK MHRA approval

On May 18, 2026, HC Wainwright reaffirmed its Buy rating on Krystal Biotech and maintained a $310.00 price objective, implying modest upside versus the prior closing price, according to a broker update summarized by MarketBeat as of 05/18/2026. The report highlighted continuing positive sentiment around the company’s commercial trajectory and gene therapy platform.

The same MarketBeat overview notes that, overall, Krystal Biotech has attracted ten Buy ratings and two Hold ratings from analysts, resulting in a consensus “Moderate Buy” rating and an average price target of about $324.11, based on data compiled as of mid-May 2026. This distribution of recommendations suggests that many covering analysts see further potential tied to the company’s current product launch and pipeline opportunities, as reflected in the summary by MarketBeat as of 05/18/2026.

In parallel with the rating confirmation, Krystal Biotech announced that the UK MHRA had granted marketing authorization for VYJUVEK for the treatment of wounds in patients with dystrophic epidermolysis bullosa with COL7A1 mutations, from birth. The approval makes VYJUVEK the first genetic medicine authorized in the UK for DEB and expands the therapy’s addressable market across Europe, according to the company’s press release relayed by StockTitan/GlobeNewswire as of 05/18/2026.

Coverage from Investing.com as of 05/18/2026 adds that Bank of America Securities recently adjusted its price target on Krystal Biotech slightly, trimming the objective from $325 to $323 while reiterating a Buy rating. The move followed what the bank described as positive financial results, underscoring that the latest regulatory progress in the UK comes on top of already improving fundamentals.

The combination of a fresh UK approval and supportive analyst commentary has kept Krystal Biotech’s stock in focus for growth-oriented investors. MarketBeat’s snapshot indicates that shares of Krystal Biotech opened at around $306.29 on Monday, May 18, 2026, on Nasdaq, close to the HC Wainwright target of $310 and not far from the broader analyst consensus target, according to MarketBeat as of 05/18/2026.

Industry trends and competitive position

Krystal Biotech operates within the broader gene therapy and rare-disease treatment landscape, which has attracted substantial investor interest due to the potential for transformative medicines and premium pricing. Regulators in the US and Europe have increasingly granted breakthrough or expedited designations to therapies targeting severe, underserved conditions, creating a framework that can support relatively rapid approvals once clinical benefit is demonstrated, a trend reflected in coverage of the sector by outlets such as Investing.com as of 05/18/2026.

Within this environment, Krystal Biotech’s focus on dermatologic gene therapies distinguishes it from many gene therapy players that concentrate on hematology or ophthalmology. That differentiation can reduce direct competition in some indications while still benefiting from shared advances in vector design, manufacturing and regulatory policy across the gene therapy field, as noted in multiple industry commentaries summarized by Invezz as of 05/2026.

However, competition in rare dermatology is expected to intensify over time as large pharmaceutical companies and other biotech firms pursue similar indications. That dynamic means that Krystal Biotech’s lead-time advantage and first-mover status with VYJUVEK in certain markets may be important in establishing relationships with patient communities, payers and specialists. Sustained investment in clinical data and post-approval studies may also be critical to maintaining a durable position, according to sector analysis cited by Investing.com as of 05/18/2026.

Why Krystal Biotech Inc matters for US investors

For US investors, Krystal Biotech is relevant both as a Nasdaq-listed growth stock and as an example of the evolving economics of gene therapy. The company’s ability to translate scientific innovation into commercial products in rare diseases is closely watched by market participants who follow emerging biotechnology names and the broader healthcare sector, as reflected in coverage by MarketBeat as of 05/2026.

Krystal Biotech’s trajectory can influence sentiment toward comparable small and mid-cap biotechnology companies, especially those pursuing in vivo gene delivery for localized diseases. Positive regulatory outcomes, such as the recent UK MHRA approval of VYJUVEK, may reinforce the perception that regulators are willing to work with innovators on complex gene therapies when clinical benefits are compelling, a narrative noted in international coverage by Investing.com as of 05/18/2026.

In addition, US-based portfolio managers focused on healthcare often look at companies like Krystal Biotech to gauge how payers respond to high-cost gene therapies in niche indications. Reimbursement decisions in the US and Europe can affect not only Krystal Biotech’s revenue trajectory but also pricing benchmarks for future therapies from other issuers, which is why developments around VYJUVEK and subsequent products tend to draw close attention in earnings and conference-call discussions summarized by data providers such as MarketBeat as of 05/2026.

Conclusion

Krystal Biotech Inc has reached an important phase in its development, moving from a clinical-stage story to a commercial gene therapy player that is expanding geographically. The recent UK MHRA approval for VYJUVEK and the Buy reiteration with a $310 price target from HC Wainwright, alongside continued positive views from other banks such as Bank of America Securities, underscore how closely the market is watching the company’s execution, according to sources including MarketBeat as of 05/18/2026 and Investing.com as of 05/18/2026. For investors, the key questions now center on how quickly VYJUVEK can scale across existing and new markets, how durable the competitive advantage of Krystal’s platform will be, and how effectively management can translate its pipeline into additional revenue streams over time, all against the backdrop of typical biotechnology risks and market volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.